About Platform Pipeline Patients Investors & News Careers Compelling clinical data fuels our platform The microbiome: Essential for health. Harnessed for medicine. The microbiome consists of trillions of microbes that live symbiotically in and on every human and are essential to our health. When key microbes are lost, the resulting dysbiosis (microbiome disruption) can increase susceptibility to immune disorders, infections, neurological conditions, cancer, and other serious conditions. We are leveraging our Human-First Discovery® platform to develop novel therapeutics designed to deliver missing microbes and their clinically relevant biochemical functions to correct dysbiosis and the conditions that emerge from it. Finch publications OCTOBER 2021 ACG 2021 CP101 Engraftment Drives Efficacy: Results from a Randomized, Placebo-Controlled Trial Evaluating CP101, an Investigational Orally Administered Microbiome Therapeutic for Prevention of Recurrent C. difficile Infection OCTOBER 2021 ACG 2021 Week 24 Efficacy and Safety Data from PRISM3: A Randomized, Placebo-Controlled Trial Evaluating CP101, an Investigational Orally Administered Microbiome Therapeutic for the Prevention of Recurrent C. difficile Infection OCTOBER 2021 THE AMERICAN JOURNAL OF GASTROENTEROLOGY CP101, an Investigational Orally Administered Microbiome Therapeutic, Increases Intestinal Microbiome Diversity and Prevents Recurrent C. difficile Infection: Results From a Randomized, Placebo-Controlled Trial JUNE 2021 THE JOURNAL OF INFECTIOUS DISEASES Beyond Fecal Microbiota Transplantation: Developing Drugs from the Microbiome OCTOBER 2020 UEG WEEK 2020 An Investigational Oral Microbiome Drug, CP101, for the Prevention of Recurrent C. difficile Infection: A Randomized, Placebo-Controlled, Multi-Center Trial (PRISM3) JUNE 2017 THE AMERICAN JOURNAL OF GASTROENTEROLOGY Successful Resolution of Recurrent Clostridium difficile Infection using Freeze-Dried, Encapsulated Fecal Microbiota; Pragmatic Cohort Study Contact us info@finchtherapeutics.com 617-229-6499 200 Inner Belt Road, Suite 400, Somerville, MA, 02143 Policies © 2021 Finch Therapeutics Group, Inc. All rights reserved.